Paul Tudor Jones’s GSK GSK Stock Holding History

Paul Tudor Jones’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$210K	Sell	4,000 -7,500	-65%	-$397K	﹤0.01%	3306
2026 Q1	$635K	Sell	11,500 -13,400	-54%	-$726K	﹤0.01%	2663
2025 Q4	$1.22M	Sell	24,900 -26,000	-51%	-$1.21M	﹤0.01%	2131
2025 Q3	$2.2M	Buy	50,900 +7,200	+16%	+$281K	﹤0.01%	1746
2025 Q2	$1.68M	Buy	43,700 +37,100	+562%	+$1.42M	﹤0.01%	1783
2025 Q1	$256K	Buy	6,600 +400	+6%	+$14.6K	﹤0.01%	2704
2024 Q4	$210K	Buy	+6,200	New	+$223K	﹤0.01%	2813

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Paul Tudor Jones's GSK Position: Q2 2023 in Review

Paul Tudor Jones sold out of GSK (GSK) in Q2 2023, closing a stake of 10,816 shares — an estimated $385K sold.

Paul Tudor Jones first reported a position in GSK in Q3 2022 and held it in 2 quarters. The position peaked at $681K in Q3 2022. 828 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

Paul Tudor Jones reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
Paul Tudor Jones sold 10,816 GSK shares in Q2 2023, an estimated $385K.
Paul Tudor Jones first reported a position in GSK in Q3 2022 and held it in 2 quarters.
Paul Tudor Jones's GSK position peaked at $681K in Q3 2022.
828 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.